GlassScriptPhysician profile
Gregory T Haunson
NPI 1902111016
$10,286.12
in general payments reported to CMS, 2019-2025
36 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $1,072 · 2021: $1,095 · 2022: $1,145 · 2023: $1,413 · 2024: $2,149 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,888.90 |
| Education | $174.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,845.96 | 2019-2025 | |
| Genzyme Corporation | $1,538.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $931.63 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $786.60 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $523.91 | 2019-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $501.96 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $475.89 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Novartis Pharmaceuticals Corporation | $461.96 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $407.85 | 2019-2025 | Targretin, Siliq, Jublia |
| Mayne Pharma Commercial LLC | $405.21 | 2019-2024 | |
| Ucb, INC. | $329.82 | 2019-2025 | Bimzelx |
| Incyte Corporation | $329.19 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $247.87 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $246.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $236.40 | 2022-2025 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $149.37 | 2023-2024 | Vtama |
| Journey Medical Corporation | $132.90 | 2019 | |
| Amgen INC. | $102.89 | 2023-2025 | Otezla, Otezla |
| Biofrontera INC. | $77.02 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $61.01 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.95 | 2022-2025 | Spevigo |
| Almirall LLC | $48.48 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $47.97 | 2020 | |
| Dermira, INC. | $45.59 | 2019-2021 | |
| Organon LLC | $44.17 | 2024-2025 | Hadlima, Vtama |
| Botanix Sb INC | $42.36 | 2025 | Sofdra |
| Celgene Corporation | $35.60 | 2019 | |
| Janssen Scientific Affairs, LLC | $32.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.75 | 2020-2021 | |
| Sandoz INC. | $20.71 | 2019 | |
| Epi Health, LLC | $17.56 | 2021 | |
| Novum Pharma, LLC | $15.40 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.66 | 2019 | |
| Fresenius Kabi USA, LLC | $13.13 | 2023 | Idacio |
| Allergan, INC. | $11.49 | 2021 | |
| Mission Pharmacal Company | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Haunson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.